Background. Inflammation is commonly associated with malnutrition and cardiovascular disease in end-stage renal failure patients. Anti-inflammatory properties of the isoflavones, a micronutrient component of soy, have been reported in several experimental models and disease conditions, but never in renal failure. We hypothesized that dietary soy isoflavones correct laboratory evidence of systemic inflammation in haemodialysis (HD) patients with underlying high blood levels of C-reactive protein (CRP). Methods. End-stage renal disease patients on chronic HD, with elevated CRP (>10.0 mg/l) were enrolled in this pilot study. The subjects were double-blind randomly distributed with 2:1 ratio to receive isoflavone-containing soy-based nutritional supplements (soy group) or isoflavone-free milk protein (control group) for 8 weeks. Serum isoflavone, inflammatory markers and nutrition markers were assessed at baseline and at the end of the treatment. Results. Thirty-two subjects were enrolled. Fifteen subjects in the soy group and 10 in the control group completed the study; five dropouts were due to acute illness and two due to food intolerance. After intervention, blood isoflavone levels were 5- to 10-fold higher in the soy group than in the control group [e.g. median genistein (25-75th percentile): 337.9 (175.5-1007) nM in the soy group vs 41.4 (22.9-100.4) nM in the control group; P < 0.001]. However, the isoflavone levels ranged widely in the soy group (e.g. genistein: 33-1868 nM) and, depending on the individual compound, four to seven subjects had end-of-treatment levels that were not different from baseline. Variation from baseline of the individual serum isoflavone levels (Δ-isoflavone) and CRP displayed a strong inverse correlation in the soy group (R = -0.599, P < 0.02). In addition, Δ-isoflavone correlated positively with the variation of albumin (R = 0.522, P = 0.05) and insulin-like growth factor-1 (R = 0.518, P < 0.05). Group levels of CRP were not statistically different after intervention although a trend towards lower levels was noted in the soy group [18.2 (12.7-29.1) mg/l at baseline vs 9.7 (5.2-20.7) mg/l at week 8; NS] but not in the control group [20.6 (9.2-38.5) vs 17.6 (9.1-40.7) mg/l]. Conclusion. These data suggest the possibility of beneficial effects of isoflavone-rich soy foods on the inflammatory and nutritional status of HD patients with underlying systemic inflammation.
|Number of pages||8|
|Journal||Nephrology Dialysis Transplantation|
|State||Published - Aug 2006|
Bibliographical noteFunding Information:
Acknowledgements. This work was supported by grants from NIH (AT00205 and AT00323 to P.F., CA71789 to A.A.F. and HL70963 to R.A.), the University of Kentucky GCRC (M01-RR02602), the NKF-Council of Renal Nutrition (to T.J.S) and the Kentucky Soybean Association. We would like to thank Lois Hill, RD, Darreldean Winkler, RD and Kyleen Ward, RD for facilitating the collection of the dietary record; the research coordinators Karen Meekins, RN, Mary Wethington, RN, and Kathy Holbrook, RN for conduction of the clinical trial; the research analyst Jason Stevens for excellent technical assistance; and Susan Gardner (VA Hospital Central Laboratory) for allowing access to her laboratory equipment. Part of this work was presented at the ASN 36th Annual Meeting, San Diego, CA, 2003 and 37th Annual Meeting, St Louis, MO, 2004, and the Fifth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, Orlando, FL, November 2003.
- C-reactive protein
ASJC Scopus subject areas